Physician profile
Erin Kiley
NPI 1720748767
$5,597.00
in general payments reported to CMS, 2019-2025
24 companies · $2,361 in 2025
The $2,361 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $237 · 2023: $1,501 · 2024: $1,498 · 2025: $2,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,301 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,300.81 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,442.47 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,023.49 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $602.23 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $537.62 | 2023-2025 | Lybalvi, Aristada |
| Corium, LLC | $434.49 | 2023-2025 | Azstarys |
| Uswm, LLC | $241.68 | 2023 | Lucemyra, Zimhi |
| Axsome Therapeutics, INC. | $232.75 | 2024-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $169.75 | 2023-2025 | Spravato, Xarelto |
| Teva Pharmaceuticals USA, INC. | $159.92 | 2024-2025 | Uzedy, Austedo Xr |
| Lundbeck LLC | $153.22 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.56 | 2022-2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $84.79 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $83.71 | 2025 | Fanapt |
| Glaxosmithkline, LLC. | $75.35 | 2022-2023 | Trelegy Ellipta |
| Supernus Pharmaceuticals, INC. | $48.05 | 2022-2025 | Qelbree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $38.48 | 2023 | Cologuard Collection Kit |
| Tris Pharma INC | $36.52 | 2025 | Dyanavel Xr, Onyda Xr |
| Noven Therapeutics, LLC | $21.11 | 2025 | Xelstrym |
| Neurocrine Biosciences, INC. | $19.97 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.21 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.40 | 2025 | Cobenfy |
| Lilly USA, LLC | $15.84 | 2023 | Trulicity, Mounjaro |
| Nestle Healthcare Nutrition INC. | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Kiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.